Furthermore, our work showing TLR9 agonist treatment can enhance survival in murine LAM could be translated into the clinic in future, particularly since TLR9 agonists have been approved for several cancers and are explored in clinical trials for lung cancer. This evidence concerns the gene TLR9 and lymphangioleiomyomatosis.